drugset / Trial / NCT05657652
CAV Regimen for R/R Ph- B-ALL
Recruiting
36 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Nantong University · collabJining Medical University · collabNorthern Jiangsu People's Hospital · collabSuzhou Hospital of Traditional Chinese Medicine · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe Second People's Hospital of Huai'an · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to investigate the efficacy and safety of cladribine, venetoclax combined with cytarabine and venetoclax (CAV regimen) for relapsed/refractory (R/R) Philadelphia Chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL).
Timeline
- Start
- 2022-10-01
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 5 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 20 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |